UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of October, 2019
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
1469.682
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
661.719
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Conrad
b)
Position/status
SVP, Human Resources
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
7.181
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
   
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
0.000026
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
 
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 42.2439
0.001
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
407.873
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053 
 
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 42.2439
17.449
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Jackson
b)
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
58.431
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
89.074
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053 
 
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 42.2439
673.667
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
2433.133
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
1.
  Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
467.749
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Thomson
b)
Position/status
PCA of Mr P Thomson (President, Global Affairs)
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
121.975
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£ 16.6032
559.520
d)
Aggregated information
 
Aggregated volume Price
N/A (single transaction)
 
 
 
 
e)
Date of the transaction
2019-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: October 15, 2019
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc
 
 
 
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more GlaxoSmithKline Charts.
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more GlaxoSmithKline Charts.